Company Information
CIN
Status
Date of Incorporation
19 September 1981
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
29 September 2023
Paid Up Capital
358,219,740
Authorised Capital
400,000,000
Directors
Venkateswara Rao Thallapaka
Director/Designated Partner
over 2 years ago
over 2 years ago
Venkaiah Chowdary Nannapaneni
Director/Designated Partner
over 2 years ago
over 2 years ago
Rajeev Nannapaneni
Director/Designated Partner
over 2 years ago
over 2 years ago
Ganapati Bhat Pavan
Director/Designated Partner
over 3 years ago
over 3 years ago
Nitin Jagannath Deshmukh
Additional Director
almost 14 years ago
almost 14 years ago
Sreerama Murthy Gubbala .
Director/Designated Partner
almost 26 years ago
almost 26 years ago
Past Directors
Sridhar Sankararaman .
Director
about 7 years ago
about 7 years ago
Lingarao Donthineni
Director
about 10 years ago
about 10 years ago
Potluri Prasad Sivaramakrishna
Director
about 10 years ago
about 10 years ago
Kali Satya Bhujanga Rao Adibhatla
Whole Time Director
over 10 years ago
over 10 years ago
Umamaheshwarrao Naidu Madireddi
Additional Director
almost 11 years ago
almost 11 years ago
Leela Digumarti .
Additional Director
about 11 years ago
about 11 years ago
Govinda Prasad Dasu
Additional Director
almost 12 years ago
almost 12 years ago
Ravindranath Cheerakuzhi Puthan Menon
Nominee Director
about 16 years ago
about 16 years ago
Mukul Sarkar
Nominee Director
almost 20 years ago
almost 20 years ago
Bhim Sain Bajaj
Director
over 23 years ago
over 23 years ago
Durga Devi Nannapaneni
Director
almost 37 years ago
almost 37 years ago
Patents
The present invention relates to an improved process for the preparation of Ibrutinib with high purity and high yields. The present process is cost effective and feasible in large scale production also. The present process avoids the mitsunobu reagent conditions also. The present Invention also relates to a process ...
A process for the preparation of highly pure crystalline imatinib base form- N of Formula (I) is disclosed. Imatinib base of this invention is suitable for conversion to pharmaceutically acceptable salts.
Present process relates to an improved and commercial process for the preparation of lapatinib of formula-I or its pharmaceutically acceptable p-toluenesulfonate salt involving novel intermediates of formulae-XVII, XVIII, and XIX. Present process utilizes Meerwein reaction as a key step in the aryl C-C bond formatio...
The invention relates to oral pharmaceutical compositions of dabigatran or a pharmaceutically acceptable salts thereof and process for the preparation of such compositions.
Present invention discloses an improved process for the preparation of Ofloxacin of formula (I) which comprises reacting 2,4-dichloro-5-fluoro-3-nitrobenzoic acid with thionyl chloride followed by methyl 3-dimethylaminoacrylate to get the acrylate derivative of formula (XXV). Reacting the compound of formula (XXV) w...
Process for preparing composition comprising Everolimus or its pharmaceutically acceptable salts and one or more pharmaceutically acceptable excipients by wet granulation by dissolving Everolimus in one or more pharmaceutically acceptable solvents.
An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutical^ acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also relates to processes for the preparation of such compositio...
The present invention relates to an improved process for the preparation of Regorafenib with genotoxic impurities at well below threshold limit and high yield. The present invention also relates to an improved process for the preparation of regorafenib form-I with high purity.
The present invention is related to an improved process for the preparation of ceritinib with high yield and high purity. The present process is cost effective and feasible in large scale production also. The present invention also related to a stable amorphous form of ceritinib and its preparation. The present inve...
Present invention relates to an improved and commercial process for the preparation of lacosamide ((R)-2-acetamido-N-benzyl-3-methoxypropanamide) of formula-I. Present process utilizes high purity crystalline solids of formula-XXXII and XIII as key intermediates. Lacosamide is indicated for the adjunctive treatment ...
Anhydrous polymorphic form-I of anti cancer drug, Lenalidomide whose chemical name is 3-(4-amino-1-oxo-1, 3-dihydro-isoindole-2-yl)-piperidine-2, 6-dione, is disclosed. Alternate methods for making anhydrous polymorphic form-I of Lenalidomide are also disclosed.
The present invention relates to a novel processes for commercial production of pharmaceutical grade octreotide using classical solution phase peptide synthesis in high yield and purity and using inexpensive amino acid derivatives. Thus the protected octapeptide alcohol Boc -D- Phe - Cys (Trt)-Phe -D - Trp - Lys (...
The present invention relates to a novel process for the preparation of Sapropterin dihydrochloride of formula (1) and its key intermedíate L-erythro-biopterm of formula (2). The present process is a simple and economically viable process for commercial production of Sapropterin dihydrochloride of formula (1) and it...
The present invention is related to an improved process for the preparation of Pomalidomide with higher yields and high purity. Particularly the present invention relates to form A preparation of Pomalidomide and its purification, wherein the present process doesn"t involve use of dioxane solvent and avoids higher t...
The present invention relates to a process for the preparation of dimethyl fumarate of formula (1) from fumaric acid of formula (3). The present process is simple, cost effective and feasible in large scale production. Dimethyl fumarate obtained by the present process is free of geno toxic impurities.
...
ABSTRACT
The present invention relates to an improved process for the preparation of amorphous form of Canagliflozin with high purity and high yield. Particularly the present invention is related to the direct isolation of amorphous form of Canagliflozin from reaction mixture and also related to purification of amo...
Present invention relates to an improved and commercial process for the preparation of 2-sustituted-2-(6-(substituted)-7-methylbenzo[d][l,3]dioxol-4-yl)acetic acid derivatives of formula-I
Wherein R1 is a O-protecting group such as methoxymethyl, ethoxymethyl, trialkylsilyl, arylmethyl, tetrahydropyran-2-yl, allyl;...
Oral pharmaceutical compositions of dimethyl fumarate and process for the preparation of such compositions.
The present invention relates to a simple and commercially feasible preparation of high purity Fulvestrant. The present invention also provides improved process for the preparation of Fulvestrant intermediates.
The present invention relates to and an improved process for the preparation of Armodafinil with high purity and high yield. The present invention also related to preparation of Armodafinil polymorphic Form-1 with a particle size of above 200|im by direct crystallization.
Disclosed is a process for the preparation of S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (I) the key intermediate for the preparation of Ambrisentan [(+)-2(S)-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid] Ambrisentan of the formula (IA) is approved under the trademark "Letairis ®" by th...
An oral pharmaceutical formulation containing an effective amount of NRC AN 019 including its pharmaceutically acceptable salts and polymorphs such as Form I Form II and Form III thereof to improve the bioavailability intended for self emulsification upon its contact with the gastro intestinal fluid. The invention a...
The present invention relates to an improved process for the preparation of Teriflunomide with high yield and high purity. The present invention also relates to a process for the preparation of teriflunomide which is free from genotoxic impurities.
The present invention relates to a novel process for the preparation of 2,5-furandicarboxylic acid of formula- (1).
(FDCA) (1)
The invention relates to an improved process for the preparation of highly pure imatinib base (99.99% HPLC purity) of formula (I) and the pharmaceutically acceptable acid addition salts thereof. This invention also relates to processes for the preparation of the intermediates in the synthesis of imatinib base.
...
A pharmaceutical solution suitable for oral administration containing an effective amount of Imatinib including its pharmaceutically acceptable salts and polymorphs such as α, β or α2 to improve the dosage uniformity, palatability and thus patient compliance. The invention also relates to a process for the preparati...
The present invention is related to an improved process for the preparation of dasatinib anhydrous crystalline Neat form N-6 with high purity and high yield. The present invention also relates to purification of dasatinib crystalline Neat form N-6.
The invention relates to synthesis and anticancer activity of novel boronic acid derivatives of formula 5 or pharmaceutical acceptable salts and esters thereof. Anti cancer activity of the compounds is evaluated by in vitro study on cancer cell lines like prostate cancer, lung cancer, head and neck cancer or breast ...
The present invention relates to a novel process for the isolation of water insoluble macrolide antibiotic rapamycin from the fermentation broth through sequential steps of biomass separation, extraction with suitable solvents and concentration. The invention also relates to separating rapamycin from the concentrate...
The present invention relates to a stable and pure polymorphic form, designated as polymorphic form-N of bortezomib (1) and processes for the preparation of the same. Bortezomib is an anti-neoplastic agent used in the treatment of multiple myeloma and mantle cell lymphoma.
The invention relates to improved processes for the preparation of imatinib mesylagte, beta form suitable for industrial operations which comprises slurrying imatinib base in a solvent selected from acetone, acetonitrile, mixture of isopropyl alcohol and water. methanol and methylene chloride, methyanol and isopropy...
The present invention relates to a novel crystalline fonn of Gefitinib and a process for its Preparation thereof. Gefitinib is 4-(31-chloro-41-fluoro anilino)- 7-methoxy-6- (3-morpholino propoxy) quinazoline and has the structural formula-I
The present invention is to provide a stable novel cryst...
The present invention relates to a novel dihydrate form of Amifostine of formula(I) and process for its preparation.
A novel process for the preparation of highly pure (>99.8%) imatinib base of Formula (I) is disclosed. Highly pure imatinib base of this invention is suitable for conversion to pharmaceutically acceptable salts.
The present invention relates to novel polymorphic forms of N-[2-(diethylamino)ethyl]-5"[(5-fluoro-l,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-254-dimethyl-lH-pyrrole-3-carboxamide-Sunitinib base (I). The present invention also relates to methods of preparing such polymorphic crystals.
THIS INVENTION DISCLOSES APROCESS FOE THE PREPARATION OF ANOVEL STABLE - CRYSTAL FROM OF LMATINIB MESYLATE WHICH COMPRISES SLURRYING IMATINIB BASE IN ISOPROPANOL AT ROOM TEMPERATURE FOLLWED BY ADDITION OF METHANE SULFONIC ACID AND MAINTAINING THE TEMPERATURE BETWEEN 75-80 C FOLLOWED BY FILTRATION.
...
A pharmaceutical formulation and its process for the preparation of controlled release gastric floating matrix solid oral dosage form of lmatinib or its pharmaceutically acceptable salts and its polymorphs such as ~, a2, Form I and Form 2 thereof for once daily administration in the form of coated tablet or minitabl...
HIGH PURITY PALONOSETRON BASE AND ITS SOLID STATE
CHARACTERISTICS
The present invention describes the process for the preparation of pure enantiomeric form of palonosetron base of formula-I, and its solid-state characteristics of said compound.
ABSTRACT
DERIVATIVES AND SALT FORMS OF MESALAMINE
The present invention relates to the acid addition salts of 5-amino salicylic acid of the formula (I) which are selected from a group consisting of a nitrate salt, a hydrobromide salt, a sulfate salt, a methane sulfonic acid salt, a ethane sulfonic acid salt, a tri...
The present invention relates to an improved and novel process for the preparation of highly pure (>99.7) l-[[[3-[2-(Dimethyl amino)ethyl]-lH-indol-5-yl]methyl]sulfonyl pyrrolidine (Almotriptan) of formula-I and its pharmaceutically acceptable salts and process for preparation thereof
Tyrosine-N-carboxy anhydride (Tyrosine-NCA, I) is one of the four amino acid building blocks used in the preparation of glatiramer acetate. The present invention describes a process for preparation of tyrosine-NCA by industrially convenient, environmentally friendly and safe process involving the reaction of triphos...
Present invention is related to three novel crystalline forms of risedronate monosodium of formula-I and processes for the preparation of same. These forms are stable and suitable for pharmaceutical formulations.
A novel and convenient method of manufacture of letrozole of formula I is described. Letrozole is an aromatase inhibitor drug used in the treatment of postmenopausal breast cancer
ABSTRACT
CROSS-LINKED DEXTRIN AS A TABLET DISINTEGRANT/EXCIPIENT
Disintegrant are the essential components of a tablet. Cross-linking of dextrin with epichlorohydrin induces hydrophobization in hydrophilic dextrin. This in turn gives good swelling power in water. Dextrin is cross-linked with various ratios of epic...
The present invention relates to a simple and novel process for the preparation of 'PURE DONEPEZIL HYDROCHLORIDE POLYMORPH -F
Very high purity (99.8%) of Donepezilhydrochloride is prepared by avoiding cumbersome chromatography procedures and by employing simple laboratory conditions.
The present invention relates to novel crystalline forms of anastrozole and process for thier preperation. anastrozole is useful, as an anti-neoplastics agent in treatment of breast cancer. The novel forms have been designated by us as forms I & Form II.
Abstract
The present invention relates to a process for the preparation of a psychotropic agent Paliperidone. Preferably, this invention relates to a method for the purification of Paliperidone by making its acid addition salts.
An improved process for purification of Zolmitriptan
The present invention relates to an improved and novel process for the purification of the Zolmitriptan (I) to get highly pure drug substance of greater than 99.8% purity.
Zolmitriptan is a 5HT1-like receptor agonist useful in the treatment and prophylaxis of mi...
Abstract
An Improved Process for Preparation of Alanine-NCA
Alanine-N-Carboxy anhydride (Tyrosine-NCA, I) is one of the four amino acid building blocks used in the preparation of glatiramer acetate. The present invention describes a process for preparation of alanine-NCA by industrially convenient, environmentally...
The present invention relates to an improved and new process for the preparation of high purity crystalline base of Lapatinib of formula-(l) having chemical name N-{3-chloro-4-[(3-fluorobenzyloxy]phenyl}-6-[5-({[2-(methanesulfonyl) ethyl]amino}methyl]-2-furyl]-4-quin -azolinamine and its pharmaceutically acceptable ...
Present invention provides a novel and improved process for the preparation of N- methyl-lH-indole-5-ethanesulfonamide of formula I. Compound of formula I is a key intermediate used in the synthesis of naratriptan hydrochloride of formula II. Hydrazone derivative of formula XL derived from the corresponding hydrazin...
A novel and environmentally friendly process for the preparation of highly pure (>99.8%) imatinib base of Formula (I) is disclosed. Imatinib base of this invention is suitable for conversion to pharmaceutically acceptable salts.
Present invention relates to novel 3-aryloxy 3-substituted propanamines of formula I, method of preparing the same and to their use in inhibiting serotonin and norepinephrine reuptake.
wherein
A is a phenyl which is optionally substituted with up to five substituents; a 1- or 2- naphthyl which is unsubst...
The invention disclosed in this application relates to novel (S)-2-amino-3- (4-amino phenyl) propanol Of the formula I .
and also to a process of its preparation. The process comprises (i) Preparing the 4-nitro-(S)-phenylalaninol of formula (IV)
by conventional methods.(ii) Reducing the n...
The present invention relates to a novel crystalline Form L of letrozole and a process for preparing the same. Letrozole is useful for the first-line treatment in post-menopausal women with hormone receptor positive (or) locally advanced (or) metastatic breast cancer.
The present invention relates to novel and stable polymorphic forms of ibandronate monosodium monohydrate of formula I and processes for their preparation. Ibandronate monosodium monohydrate is useful, as bone resorption inhibitor. The novel crystalline forms are designated as Form I, Form II and the amorphous iband...
The present invention relates to Recombinant human Granulocyte Colony Stimulating Factor (G-CSF) and describes a novel purification process for a simple, economically feasible, largely scalable production of pharmaceutically acceptable grade product with high recovery of rhG-CSF expressed from bacterial cells. The i...
The present invention relates to Recombinant human Granulocyte Colony Stimulating Factor (G-CSF) and describes a novel process for high-level expression, a simple, economically feasible, largely scalable production of RPG-CSF— from bacterial cells. The invention comprises of the development of transcriptional and tr...
The present invention relates to novel crystalline forms, designated as Form I and Form II of Palonosetron Hydrochloride ((3as)-2[(3s)-l-Azabicyclo[2.2.2]Oct-3-yl]-2,3,3a,4,5,6-hexahydro-lH-benz[de]isoquinoline-l-one mono hydrochloride) and processes for their preparation.
I
Palonosetron Hydrochloride is useful...
ABSTRACT
CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES
The present invention relates to a particular form of the (3,5-bis trifluoromethyl)-N-[4- methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I), processes for the preparation thereof, pharmaceutical compositions containing this crystal...
The present invention relates to three novel crystalline forms of Erlotinib hydrochloride and method of preparation thereof. Erlotinib hydrochloride is N-(3-ethynylphenyl)-6,7-bis(2- methoxy ethoxy)-4-quinazolinamine hydrochloride of formula-(I). The present invention provides stable novel crystalline forms of Erlot...
The present invention provides a cost effective, high yielding and industrially feasible process for the preparation of highly pure Bicalutamide (N-4-[4-cyano-3-(trifluoromethyl) phenyl]-3-[4-fluorophenyl) propanamide of formula-I starting from methacrylolyl chloride starting from methacrylolyl chloride in essential...
Imatinib base (I) is prepared by a novel method by reduction of N-(2-Methyl-5-nitrophenyl)-4-(3-pyridyl)-2-pyrimidine amine (IV) employing sodium disulphide and condensing the resulting amine N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidinamine (II) with the acid chloride 4-[(4-Methylpiperazin-l-yl) methyl]benz...
Formula-I where HX is succinic acid, l-hydroxy-2-naphthoic acid, L- (+)-tartaric acid, 3-hydroxy-3-methylglutaric acid (meglutol), formic acid, acetic acid, propionic acid, d, 1-lactic acid benzoic aicd, fumaric acid, and p-toluenesulphonic aicd.
The present invention relates to an improved and novel process for the preparation of highly pure (>99.8) N-(2,6-Dimethyl phenyl)-4-[2-hydroxy-3-(2-methoxy phenoxy) propyl] -1-piperazine acetamide (Ranolazine) of formula-I and its pharmaceutically acceptable salts process for preparation thereof
...
ABSTRACT Improved Process for Preparation of Eptifibatide by Fmoc Solid Phase Synthesis
Eptifibatide is a cyclic heptapeptide containing six amino acids and one mercaptopropionyl (des-aminocysteine, Mpa) residue. An interchain disulphide linkage is formed between the cystiene amide and mercaptopropionyl moieties. I...
The present invention relates to two novel and stable polymorphic forms, namely Form I and Form II of bortezomib (1) and processes for the preparation of these forms. Bortezomib is an anti-neoplastic agent used in the treatment of multiple myeloma.
The present invention relates to an improved and novel process for the preparation of highly pure (>99.8%) (+)-2(S)-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid (Ambrisentan) of formula-I.
This invention relates to an improved process for the preparation of Nilotinib of formula (I)
starting from 3-amino-4-methylbenzoic acid of the formula (II) through novel intermediates
4-methyl-N-[3-(4-methyl-lH-imidazol-l-yl-5-(trifluoromethyl)phenyl]-3-nitro-benzamide of the
formula (III), 4-methyl-N-[3-(4-meth...
The invention disclosed in this application relates to an improved process for the preparation of highly pure (>99.9%) 5-arnino salicylic acid which comprises dissolving 5-Nitro salicylic acid of formula (III) in aqueous alkaline solution, hydrogenating the alkaline solution with hydrogen gas in the presence of a...
ABSTRACT METHOD FOR PREPARING AN OPTICALLY ACTIVE FROVATRIPTAN
Disclosed Process for the preparation of optically active Frovatriptan or a salt comprising
of
(i) Combining the racemic 6-cyano-3-N-methylamino-l,2,3,4-
tetrahydrocarbazole of formula (I) with D-Pyroglutamic acid as the resolving agent in a Resol...
The present invention relates to a novel and improved process for the preparation of tolterodine of formula I. Key steps involved in the process are a vinyl Grignard reactioll on a benzophenone derivative of formula XXI to get the vinyl carbinol derivative of formula XXII and rearrangement of the carbinol derivative...
The present invention discloses an improved and novel process for the preparation of erlotinib (N-(3-ethynylphenyl)-6?7-bis(2-methoxyethoxy)-4-quinazolinamine) of formula (1), which comprises: (i) demethylation of commercially available 6,7-dimethoxy-4(3H)-quinazolinone of formula (8); acetylation using acetic anhyd...
The present invention relates to an improved and industrially viable process for the preparation of high purity ≥ 99.8% chemical of paliperidone of formula-I (3-[2-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-l-piperidinyl]ethyl]-6,7,8,9-tetra-hydro-9-hydroxy-2-methyl-4H-pyrido[l,2-a]pyrimidin-4-one), involving the nove...
ABSTRACT
AN IMPROVED PROCESS FOR THE PREPARATION OF PURE PALONOSETRON HYDROCHLORIDE
The present invention relates to an improved and industrially viable process for the preparation of high purity >99.8% chemical and >99.8% chiral of palonosetron hydrochloride of formula-I ((3as)-2[(3s)-l-azabicyclo [2.2.2] oct-3-y...
This invention relates to a process for the preparation of (3-trifluoromethylsulfonyl)-N-[4- methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula (I)) starting from 4-methyl-2-nitro-aniline (formula (II)) through intermediates (3- trifluoromethylsulfonyl)-N-[4-methyl-3-nitrophenyl]-benzamide (formu...
Disclosed is a process for the preparation of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3- cyanophenyl)-5-thiazolecarboxylate (I) the key intermediate for the preparation of [2-[3- cyano-4-(2-Methyl-propoxy)phenyl]-4-methyl-5-thiazole carboxylic acid] (Febuxostat, 1(A)) is approved under the trademark Uloric ® by the ...
A Novel Pharmaceutical Composition Containing Sildenafil Salt For Treating Male Erectile Dysfunction
The invention disclosed in this application relates to a novel pharmaceutical composition containing sildenafil useful for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes. The composition is also effective in patients with erectile dysfunction due to s...
The present invention relates to a novel freeze -dried pharmaceutical composition useful for the treatment of migraine and associated symptoms at a reduced total dose of active substance than required for oral administration in the form of a tablet comtaining a porous matrix net work of a water soluble or water disp...
The present invention relates to an improved and novel process for the preparation of high purity crystalline base of Lapatinib of formula-(l) having chemical name N-{3-chloro-4-[(3- fluorobenzyloxy]phenyl}-6-[5-({[2-(methanesulfonyl) ethyl]amino}methyl]-2-furyl]-4-quin - azolinamine and its pharmaceutically accepta...
This invention relates to an improved process for the preparation of omeprazole of the formula 1 starting from 4-nitro-2.3.5-trimethylpyridine-N-oxide and through novel intermediates 2-hydroxymethy1-3.5-dimethy1-4-intro pyridine of the formula II and novel 2- chloromethy1-3,5-dimethy1-4-nitro pyridine of the for...
The invention disclosed in this application relates to an improved pharmaceutical formulation containing omeprazole, which is useful for the treatment of gastro intestinal diseases. The formulation is stable against gastric juices.
The formulation of omeprzole is in the form of pellets filled into capsules. The pel...
In view of the great potential the quinazoline class of compounds offer, we started the synthesis and screening of a large number of new chemical entities with novel structural features. It has been surprisingly and unexpectedly found that quinazolines having 3-Ethynyl anilino group at the 4th position and specifica...
The invention disclosed in this application relates to an improved pharmaceutical formulation containing aspirin, which is useful for the prevention of cardiovascular diseases such as stroke and decrease in recurrence of a heart attack and other heart problems, and is protected against gastric juices, in the form of...
The present invention relates to novel intermediates useful for the preparation of novel phyenylamino pyrimidine derivatives. Pharmaceutical composition containing the novel phenylamino pyrimidine derivatives and the processes for their preparation. The invention particularly relates to novel phenylamino pyrimidine ...
The present invention relates to an improved process for the preparation of N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine) methyl]-2,4-
dimethyl-lH-pyrrole-3-carboxamide - Sunitinib base of formula-I and its pharmaceutically acceptable malate salt of formula-I(a).
...
The invention relates to novel stable polymorphic form FC-1 of Febuxostat [2-[3-cyano-4-(2-Methyl-propoxy)phenyl]-4-methyl-5-thiazole carboxylic acid]. The invention also provides process for the preparation of novel stable polymorphic form FC-1 with >99.8% HPLC purity.
The present invention provides a novel method for producing rapamycin by submerged fermentation which comprises cultivating Streptomyces hygroscopicus (CBS 773.72) and mutants thereof. The present invention provides a high yielding mutant culture MTCC5681 from Streptomyces hygroscopicus CBS 773.72. This culture is c...
The present invention relates to an improved and commercially viable process for the preparation of > 99.8% pure plerixafor base (1) by HPLC. The process of the present invention involves simple crystallization techniques to isolate the compounds at each step without employing the laborious column chromatography tec...
A pharmaceutical suspension suitable for oral administration containing an effective amount of gefitinib to improve palatability, ensuring adequate therapeutic levels of drug concentration in comparison to the commercial tablet dosage form and thus patient compliance can be achieved. The invention also relates to a ...
The present invention relates to an improved process for the preparation of high purity formoterol and its pharmaceutically acceptable salts of foumula-I(C)
A Pharmaceutical composition comprising teriflunomide or salts thereof and
colloidal silicon dioxide.
Bivalirudin is 20 amino acids containing polypeptide and used as anticoagulant. The present invention describes simple, cheap, convenient process for preparation of bivalirudin by solid phase synthesis using fmoc chemistry. The linear peptide was assembled on chlorotrityl chloride polystyrene resin. The assembled pe...
The invention relates to pharmaceutical compositions of pomalidomide comprising pomalidomide and binder or filler at amount of at most 89% weight percent of total weight of the composition and process for the preparation of such compositions.
The present invention relates to pharmaceutical compositions comprising Bruton’s tyrosine kinase inhibitor. More particularly, the present invention relates to a tablet composition comprising Ibrutinib and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
...
The present invention relates to pharmaceutical compositions comprising Ibrutinib. More particularly, the present invention relates to a tablet composition comprising Ibrutinib and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
The present invention relates to an improved process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-l-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate (1/1) compound of formula-la and its novel crystalline forms. The said compound of formula-la is represented by the foll...
The present invention relates to pharmaceutical compositions comprising Lenalidomide. More particularly, the present invention relates to a stable composition comprising anhydrous Lenalidomide Form I and one or more pharmaceutically acceptable excipients and process for preparing such compositions.
...
Present invention relates to an improved process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.
The present invention relates to an improved process for the preparation of thalidomide with high purity and high yield. The present invention also related to preparation thalidomide polymorphic a-form by direct crystallization.
ABSTRACT
The present invention relates to process for the preparation of intermediates of Eribulin and process for the preparation of the same. The process of the present invention involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale.
...
which comprises:(i preparation of the compound of the formula-IV by reducing the magnesium salt of benzophenone derivative of the formula-III using sodium borohydride in the presence of a protic solvent and cyclization of the compound of the formula-IV with an acid catalyst in a non-polar solvent to ge...
This invention discloses an improved process for the preparation of l-(4'-fluorophenyl)-l,3-dihydro-isobenzofiiran-5 carbonitrile of formula-ll, which is useful for the preparation of citalopram of formula-Ill, a well-known antidepressant available in the market. Process for the preparation of co...
This invention discloses an improved process for the preparation of 1-( 41-fluorophenyl)- 1,3-dihydro-isobenzofuran-5-carbonitrile of formula-II, which is useful for the preparation of citalopram, a well-known antidepressant drug available in the market. Process for the preparation of compound of formu...
This invention discloses an improved process for the preparation of 4-bromo- (2- hydroxymethyl)-phenyl-(4'-fluorophenyl) methanol of formula-VIII, which is useful for the preparation of citalopram. Process for the .preparation of compound of formula- vrn comprises: (i) Reaction of 5-bromophthalide with...
The invention disclosed in this application relates to an extended release oral pharmaceutical composition containing amoxicillin intended for releasing at a specific site for maximum absorption upon oral administration. The pharmaceutical composition is useful for maintaining the desired therapeutic concent...
The invention disclosed in this application relates to novel (S)-2-amino-3-(4-amino phenyl) propanol Of the formula I . and also to a process of its preparation .The process comprises (i) Preparing the 4-nitro-(S)-phenylalaninol of formula (IV) by conventional methods.(il) Reducin...
The present invention relates to an improved pharmaceutical composition, in the form of a soft gel capsule resistant to digestive juice. The composition of the present invention is made up of gelatin and an enteric polymer in the form of free acid or its salt, containing used in the treatment of duodenal ulc...
The present invention relates to improved pharmaceutical preparations comprising an inert core, constituted by starch and sugar, surrounded by active coating containing enantiomers, sahs of the enantiomers of omeprazole such as esomeprazole in micronised form, which is mixed with pharmaceutically acceptable ...
The present invention discloses an improved process for the preparation of high purity escitalopram base of formula-I by reacting the acid addition salt of formula-XVIII with copper (I) cyanide and with or without copper (I) iodide in dimethylformamide medium at 145-150°C. Cyanation on the acid addition salt...
Controlled release oral pharmaceutical mucoadhesive matrix formulation containing a therapeutically effective amount of tolterodine or its pharmaceutically acceptable salts, prodrugs and metabolites thereof dispersed in a rate controlling polymeric matrix comprising (1) a pH independent gelling polymer, such...
ABSTRACTPresent invention discloses an improved process for the preparation of high purityanastrozole (2,2'-[5-(lH-l,2,4-triazoI-l-ylraethyl)-l,3-phenylene]di{2-methylpropio-nitrile) consisting of: (i) halogenation of 5, a, a, a', a'-pentamethy!-l,3-benzenediacetonitrile; (ii) reaction with...
DELAYED RELEASE FORMULATION CONTAINING VENLAFAXINE AND A PROCESS FOR PREPARING THE SAMEA delayed release oral pharmaceutical formulation containing therapeutically effective amount of Venlafaxine or its pharmaceutically acceptable salts, prodrugs, and metabolites thereof to maintain steady state blood ...
The present invention relates to an improved process for the preparation of escitalopram of the formula-I which consists of a sequential double Grignard reaction on 5-iodophthalide to get the dihydroxy compound of formula-XVI, its resolution using a chiral acid, cyclization of resolved compound of the formul...
This invention discloses an improved process for the preparation of 5-bromo-I-(4- fluorophenyl)-1,3-dihydroisobenzofuran of formula-I, which is useful for the preparation of antidepressant drug citalopram. Process for the preparation of compound of formula- I comprises: (i) A Grignard reac...
A chemical method for the separation of letrozole precursor 4-[1-1,2,4-triazolyl)methyl]benzonitrile of formula (I) from the isomeric unwanted byproduct 4-[l-(l,3,4-triazolyl)methyl]ben2onitrile of formula (II) of the reaction in which it is produced is described.
Present invention discloses an improved process for the preparation of -(2-methylaminoethyl)-4-fluorophenylmethanol of formula-I by N-debenzylating the acid addition salt of 3-(benzyl(methyl)amino)-l-(4-fluorophenyl)propan-l-ol of formula-V under heterogeneous hydrogenation conditions. Hydrogenation of acid...
The present invention relates to novel crystalline form, Form N of Ticagrelor and process for preparation of the same.
The present invention relates to improved process for the production of Pirfenidone which is comprises reacting the compound of 5-methyl-2(1H)-pyridone of formula (III)
with bromobenzene (IV) in polar solvent, in presence of base and activated Cu powder to obtain the compound of formula (I). The present invent...
The present invention relates to a process for the preparation of stable and pure amorphous form of Idelalisib. Further, the present process is simple, more economical, cost effective and efficient method of manufacturing that is suitable for industrial scale-up having a high degree of chromatographic purity.
...
The invention relates to oral pharmaceutical compositions comprising Ticagrelor and pharmaceutically acceptable polymer in a ratio of 1:0.1 to 1:1 in the form of solid dispersion and process for the preparation of such compositions.
The present invention relates to an improved and industrially viable process for the preparation of high pure palbociclib of formula-1. The present invention involves simple crystallization techniques avoiding column chromatographic techniques and the process conditions can be easily adopted for scale-up studies.
...
The present invention relates to an improved process for the preparation of Elbasvir compound of Formula-I through its novel salt. The compound of Formula-I is represented by the following structural formula:
The present invention provides a novel process for the preparation of 2-(4-Ethyl-3-iodophenyl)-2-methylpropanoic acid of Formula (I), which is a key intermediate in the synthesis of Alectinib or its salt of Formula (II).
The present invention relates to novel intermediates of Eribulin and process for the preparation of the same. The process of the present invention is commercially viable and can be easily adopted for plant scale operations. The present invention relates to tetrahydrofuran compounds of formula I, X, XI, D and B.
...
The present invention relates to an improved process for the preparation of 4-[3-chloro-4-(N’-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate compound of formula-1a. The said compound of formula-1a is represented by the following structural formula:
Formula-1a
AN IMPROVED PROCESS FOR THE PREPARATION OF ANTHRANILAMIDE DERIVATIVES
ABSTRACT
The present invention relates to an improved process for the preparation of anthranilamide derivatives. More particularly, the present invention relates to an improved process for the preparation of Chlorantraniliprole-(Ia) a...
STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING SACUBITRIL-VALSARTAN COMPLEX
ABSTRACT
The present invention relates to pharmaceutical compositions comprising sacubitril-valsartan complex. More particularly, the present invention relates to a stable composition comprising trisodium salt of sacubitril-valsartan comple...
The present invention relates to a process for the preparation of sorafenib tosylate form III from sorafenib base through sorafenib tosylate methanol solvate. The present invention relates to an improved process for the preparation of Sorafenib tosylate form III with high purity and high yield. The present process c...
The present invention relates to a novel process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo [2,3-d]pyrimidine-6-carboxamide succinate (1/1) compound of formula-1a. The said compound of formula-1a is represented by the following structural formula:
Formu...
The present invention provides an improved process for the preparation of Neratinib Maleate of formula (I) and intermediate thereof
The present invention relates to pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride. More particularly, the present invention relates to a tablet composition comprising trifluridine, tipiracil hydrochloride and one or more pharmaceutically acceptable excipients and process for preparing ...
The present invention provides an improved process for the preparation of Sugammadex sodium of formula (I) having more than 98.5% purity along with less than 1.0% monohydroxy Sugammadex sodium and less than 0.15% any other known or unknown impurities by HPLC.
“AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF”
ABSTRACT
The present invention relates to an improved process for the preparation of N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide compound of formula-...
The present invention relates to a process for the preparation of high pure Eribulin and Eribulin Mesylate. The present invention involves preparation of high pure Eribulin and its mesylate salt involving chiral acid addition salts of Eribulin.
“PROCESS FOR THE PREPARATION OF ECTEINASCIDIN DERIVATIVE AND ITS INTERMEDIATE”
ABSTRACT
The present invention relates to an improved and industrially viable process for the preparation of Trabectedin. The present invention also relates to an improved and industrially viable process for the preparation of Trabe...
The present invention relates to new HPLC methods for the analysis of the drug substance Sugammadex sodium. The present invention also relates to a method for analysing a substance, comprising the detection and optional quantification of one or more specific impurities.
PHARMACEUTICAL COMPOSITIONS COMPRISING OSIMERTINIB
ABSTRACT
The present invention relates to pharmaceutical compositions comprising a tyrosine kinase inhibitor. More particularly, the present invention relates to a composition comprising Osimertinib or a pharmaceutically acceptable salts thereof and one or more ph...
“A PROCESS FOR THE PREPARATION OF VENETOCLAX AND ITS POLYMORPHS THEREOF”
ABSTRACT
The present invention relates to a process for the preparation of 4-(4-{[2-(4-chlorophenyl)-4,4dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo...
PHARMACEUTICAL COMPOSITIONS COMPRISING ALECTINIB
ABSTRACT
The present invention relates to pharmaceutical compositions comprising a tyrosine kinase inhibitor. More particularly, the present invention relates to a composition comprising Alectinib or a pharmaceutically acceptable salts thereof and one or more pharm...
AN IMPROVED PROCESS FOR THE PREPARATION OF BARICITINIB
ABSTRACT
The present invention provides an improved process for the preparation of Baricitinib of formula (I),
Formula (I)
A NOVEL PROCESS FOR THE PREPARATION OF CHLORANTRANILIPROLE
The present invention relates to a novel process for preparation of Chlorantraniliprole of Formula-I.
IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING OSIMERTINIB
ABSTRACT
The present invention relates to immediate release pharmaceutical compositions comprising a tyrosine kinase inhibitor. More particularly, the present invention relates to immediate release compositions comprising Osimertinib or a phar...
IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PALBOCICLIB
ABSTRACT
The present invention relates to immediate release pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to immediate release pharmaceutical compositions comprising Palbociclib or ...
“NOVEL CRYSTALLINE FORM OF TAFAMIDIS AND ITS PROCESS THEREOF”
Abstract
The present invention relates to novel crystalline Forms of Tafamidis and process to prepare thereof. The present invention also relates to process of Tafamidis N-methyl-D-glucamine.
PHARMACEUTICAL COMPOSITIONS COMPRISING RIBOCICLIB
ABSTRACT
The present invention relates to pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to immediate release pharmaceutical compositions comprising Ribociclib or a pharmaceutically acceptable salt the...
ABSTRACT
The present invention provides an improved process for the preparation of (12aR)-3,4,12,12a-tetrahydro-7-(phenylmethoxy)-1H-[1,4]oxazino[3,4-c] pyrido[2,1-f] [1,2,4]triazine-6,8-dione of Formula (I).
Formula I
which is a key intermediate in the synthesis of Baloxavir Morboxil of Formula (II)...
ABSTRACT
The present invention relates to an improved process for the preparation of anhydrous crystalline Form-I of Boscalid.
“CO-CRYSTAL OF UPADACITINIB AND DIACETYL-D-TARTARIC ACID AND PROCESS FOR THE PREPARATION THEREOF”
ABSTRACT
The present invention relates to a Co-crystal of Upadacitinib. More particularly, the present invention relates to a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (...
ABSTRACT
The present invention relates to an improved process for the preparation of (N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine compound of formula-1 and its salt & polymorphs thereof which is represented by the following structural...
The present disclosure provides a fungicidal composition comprising trifloxystrobin and tebuconazole. An aspect of the present disclosure provides a fungicidal composition, said composition comprising: (a) trifloxystrobin in an amount ranging from 1 to 50 wt. % by weight of the composition; (b) tebuconazole in an am...
ABSTRACT
IMPROVED PROCESS FOR THE PREPARATION OF
RELEBACTAM MONOHYDRATE
The present invention relates to an improved process for the preparation of Relebactam monohydrate having chemical name [(2S,5R)-7-Oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate monohydrate of formula...
ABSTRACT
The present invention provides a novel process for the preparation of Selinexor of Formula-(I) using novel intermediate compounds and it’s process thereof.
The present disclosure generally relates to the technical field of herbicidal compositions. More particularly, the present disclosure provides a storage stable liquid composition of pinoxaden. An aspect of the present disclosure provides a liquid herbicidal composition, said composition comprising: (a) pinoxaden in ...
ABSTRACTA safe, cheap commercial process for preparing Isosorbide-5-mononltrate is developed. Aqueous 70% D-sorbitoi is dehydrated to isosorbide and acetylated and purified to get Isosorbide-2-acetate. The latter is nitrated with acetyl nitrate and the product Isosorbide-2-acetate-5-nitrate is deacetyl...
The invention discloses a simple, economical, and effluents-free process for the preparation of 3- and 4-aminophthalimide of formula-I, by reduction of the corresponding nitrophthalimides of formula-II under heterogeneous hydrogenation conditions using Pd, Pt, Ni catalysts at different temperatur...
ABSTRACTThe present invention relates to a simple two step cost-effective and high yielding process for the preparation of 2-Hydroxy-3-methoxy-5-allyl benzannides of formula-(I) involving the novel synthesis of the Intermediate 2-Hydroxy-3-methoxy-5-allyl benzoic acid of formula (II) Where ...
This application discloses an improved process for the preparation of the compound of formula-I, a key intermediate used in the synthesis of terbinafine of the formula-IL Process is involving converting tertiary-butylacetylene to its Grignard derivative via trans metallation using lower alkylmagnesium halide...
Present invention relates to an improved one-pot process for the preparation of imidazol-1-ylacetic acid of the formula I. The process comprises reacting imidazole with methyl chloroacetate in the presence or absence of a phase transfer catalyst and a base, in a dipolar aprotic solvent medium and hydrolyzing...
ABSTRACT
The present invention relates to an improved process for the preparation of advanced intermediate of Formula-I of Chlorantraniliprole. And also relates to an economically viable process for key starting material of Formula-II.
The present invention provides a process for the preparation of Tipiracil HCl of Formula (I) and intermediate thereof with improved yields and purities.
The present invention relates to an improved, high yielding and industrially viable process for the preparation of high pure Lapatinib of formula (1). The present invention involves simple crystallization techniques avoiding column chromatographic techniques and the process conditions can be easily adopted for scale...
ABSTRACT
The present invention relates to pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to a composition comprising Neratinib or a pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients and process for preparin...
NOVEL PROCESS FOR THE PREPARATION OF ACALABRUTINIB INTERMEDIATES
ABSTRACT
The present invention relates to an improved and industrially viable process for the preparation of Acalabrutinib Intermediates. The present invention involves less expensive reagents, solvents and the process conditions can be easily ado...
The present invention relates to an improved process for the preparation of Osimertinib mesylate with high purity and high yield.
NOVEL PROCESS FOR THE PREPARATION OF ACALABRUTINIB AND ITS INTERMEDIATES
ABSTRACT
The present invention relates to an improved and industrially viable process for the preparation of Acalabrutinib and its Intermediates. The present invention involves less expensive reagents, solvents and the process conditions c...
ABSTRACT
The present invention relates to a process for the preparation of Eribulin Intermediates. The present invention involves less expensive solvents and the process conditions can be easily adopted for commercial scale.
PHARMACEUTICAL COMPOSITIONS COMPRISING PALBOCICLIB
ABSTRACT
The present invention relates to compositions comprising a kinase inhibitor. More particularly, the present invention relates to compositions comprising Palbociclib or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptab...
PHARMACEUTICAL COMPOSITIONS COMPRISING ACALABRUTINIB
ABSTRACT
The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib or a pharmaceutically acceptable salt thereo...
PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB
ABSTRACT
The present invention relates to pharmaceutical compositions comprising a tyrosine kinase inhibitor. More particularly, the present invention relates to a composition comprising Nilotinib or a pharmaceutically acceptable salt thereof and one or more ph...
The present invention relates to an improved process for the preparation of optically pure form of (S)-(-)-Garner aldehyde chemically known as 1,1-dimethylethyl-2,2-dimethyl-4-(S)-formyloxazolidine-3-carboxylate of formula (1). It is one of the key chiral synthons used in the synthesis of Trabectedin of formula (2) ...
The present invention provides a novel process for the preparation of Trabectedin intermediate of compound of formula-I(a).
Formula-I(a)
The present invention provides an improved process for the preparation of Trabectedin intermediate of compound of formula-I(a).
Formula-I(a)
AN IMPROVED PROCESS FOR THE PREPARATION OF TRABECTEDIN
ABSTRACT
The present invention is related to novel process for preparation of Trabectedin which involves less expensive reagents, solvents and the process conditions can be easily adopted for commercial scale.
NOVEL CRYSTALLINE POLYMORPH OF LURBINECTEDIN AND IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN
ABSTRACT
The present invention is related to novel crystalline polymorph, Form-N of Lurbinectedin and process for preparation of Lurbinectedin.
PHARMACEUTICAL COMPOSITIONS COMPRISING ELAGOLIX
ABSTRACT
The present invention relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone antagonist (GnRH antagonist). More particularly, the present invention relates to pharmaceutical compositions comprising Elagolix or a pharmaceutically...
“Improved process for the preparation of 7-(morpholinyl)-2-(N-piperazinyl)methylthieno[2, 3-c]pyridine derivatives”
ABSTRACT
The present invention describes an improved second generation process for the synthesis of NRC-1111 (1, 5-[2-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-7-(4-morpholinyl)thi...
AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB PHOSPHATE
ABSTRACT
The present invention relates to an improved process for the preparation of Ruxolitinib phosphate (1) using novel intermediate compound of Formula (14). The present invention also relates to intermediate compound of Formul...
ABSTRACT
The present invention relates to an improved process for the preparation of Crystalline Form-A of Cyantraniliprole of Formula-I.
ELAGOLIX COMPOSITIONS
ABSTRACT
The present invention relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone antagonist (GnRH antagonist). More particularly, the present invention relates to pharmaceutical compositions comprising Elagolix or a pharmaceutically acceptable salt thereof a...
AN IMPROVED PROCESS FOR THE PREPARATION OF ERDAFITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS & POLYMORPHS THEREOF
ABSTRACT
The present invention relates to an improved process for the preparation of N-(3,5dimethoxyphenyl)-N’-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl) quinoxalin-6-yl]ethane-1,2-diamine co...
AN IMPROVED PROCESS FOR THE PREPARATION OF SELUMETINIB SULFATE
ABSTRACT
The present invention relates to an improved process for the preparation of Selumetinib sulfate of Formula-(I).
Formula-(I)
Abstract
The present invention relates to an improved process for the preparation of Risdiplam compound of Formula-I. The present invention also relates to novel intermediates of Risdiplam compound of Formula-I and process for the preparation of the same.
Formula-I
“A PROCESS FOR THE PREPARATION OF BEMPEDOIC ACID”
ABSTRACT
The present invention relates to a process for the preparation of 8-hydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid compound of formula-1 which is represented by the following structural formula:
Formula-1
“NOVEL SALTS OF INFIGRATINIB AND ITS INTERMEDIATE”
ABSTRACT
The present invention related to an improved process for the preparation of Infigratinib and its pharmaceutical salts. The present invention also provides purification of Infigratinib from novel salts and intermediates.
PHARMACEUTICAL COMPOSITIONS COMPRISING ACALABRUTINIB MALEATE
ABSTRACT
The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib maleate and one or more pharmaceutic...
The invention relates to the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (preferably recurrent squamous cell carcinoma of the head and neck) with a compound which is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceuti...
ABSTRACT
The present invention relates to an improved process for the preparation of 2-Amino-5-cyano-3, N-dimethylbenzamide of Formula-I, which is an advanced intermediate of Cyantraniliprole.
ABSTRACT
The present invention relates to an improved process for the preparation of 2-Amino-5-chloro-3,N-dimethylbenzamide of Formula-I, which is an advanced intermediate of Chlorantraniliprole.
The present disclosure provides a liquid composition of Cyantraniliprole. An aspect of the present disclosure provides a liquid insecticidal composition comprising: (a) Cyantraniliprole in an amount of 0.5-50 wt.% by weight of the composition; (b) at least one other biologically active agent in an amount of 0 -20 wt...
NOVEL POLYMORPHIC FORMS OF ASCIMINIB AND ITS PHARMACEUTICAL SALTS THEREOF
ABSTRACT
The present invention relates to an improved process for the preparation of Asciminib comprising novel process intermediates. The invention also described the novel polymorphic forms of Asciminib and its pharmaceutical salts.
...
“A PROCESS FOR THE PREPARATION OF BELZUTIFAN AND ITS NOVEL INTERMEDIATES THEREOF”
ABSTRACT
The present invention relates to a process for the preparation of 3-[[(1S,2S,3R)-2,3-Difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5-fluorobenzonitrile compound of formula-1 which is represented ...
“PROCESS FOR THE PREPARATION OF 7-CHLORO-6-FLUORO-(1M)-1-[4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL]PYRIDO [2,3-D] PYRIMIDINE-2,4(1H,3H)-DIONE (M-DIONE)”
ABSTRACT
The present invention relates to a process for the preparation of 7-chloro-6-fluoro-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]pyrido[2,3-d]pyrimidin...
“A PROCESS FOR THE PREPARATION OF PURE CRYSTALLINE RIMEGEPANT AND ITS SALTS THEREOF”
ABSTRACT
The present invention relates to an improved process for the preparation of (5S,6S,9R)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b] pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-y...
AN IMPROVED PROCESS FOR THE PREPARATION OF NIRAPARIB TOSYLATE MONOHYDRATE
ABSTRACT
The present invention relates to an improved process for the preparation of Niraparib Tosylate monohydrate of Formula (I).
Formula (I)
STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ERDAFITINIB
ABSTRACT
The present invention relates to stable pharmaceutical compositions comprising a kinase inhibitor. More particularly, the present invention relates to stable tablet compositions comprising Erdafitinib and one or more pharmaceutically acceptable...
“A PROCESS FOR THE PREPARATION OF SOTORASIB AND ITS NOVEL INTERMEDIATES THEREOF”
ABSTRACT
The present invention relates to a novel process for the preparation of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]py...
ABSTRACT
BIPHENYL PYRIDINE RIGID COMPOUNDS WITH POLYCYCLIC HETEROCYCLES USEFUL AS DUAL IMMUNE CHECKPOINT INHIBITORS
This present invention relates to small molecules which are biphenyl pyridine rigid compounds with polycyclic heterocycles therapeutically useful as immune modulators. These compounds disrupt t...
“AN IMPROVED PROCESS FOR THE PREPARATION OF TIVOZANIB HYDROCHLORIDE HYDRATE”
Abstract
The present invention relates to an improved process for the preparation of Tivozanib hydrochloride hydrate compound of Formula-I.
Formula-I
AN IMPROVED PROCESS FOR THE PREPARATION OF DEUCRAVACITINIB
ABSTRACT
The present invention provides an improved process for the preparation of Deucravacitinib of Formula-(I),
Formula-(I)
Registered Trademarks
[Class : 5] Insecticides, Pesticides, Herbicides, Fungicides And Weedicides
[Class : 5] Medicinal And Pharmaceutical Preparations
[Class : 5] Fungicides, Insecticides And Herbicides
View +215 more Brands for Natco Pharma Limited.
Charges
08 March 2011
Allahabad Bank
520 Crore
18 October 2016
Kotak Mahindra Bank
50 Crore
29 March 2011
Export Import Bank Of India
50 Crore
22 June 2015
Citi Bank N.a.
12 Crore
21 December 2004
Export - Import Bank Of India
20 Lak
07 November 1995
Export Import Bank Of India
14 Crore
13 November 1992
Central Bank Of Commrce;
53 Lak
09 December 1994
Oriental Bank Of Commerce
97 Lak
13 November 1992
Oriental Bank Of Commerce
1 Crore
13 November 1992
Oriental Bank Of Commerce
1 Crore
22 December 2014
Citi Bank N.a.
60 Crore
17 April 2010
Axis Bank Limited
80 Crore
10 May 2012
Icici Bank Limited
40 Crore
26 August 2010
Export Import Bank Of India
44 Crore
24 March 2011
Barclays Bank Plc
35 Crore
22 January 2010
Citi Bank N.a.
20 Crore
13 March 1997
State Bank Of India
10 Crore
05 November 1992
Allahabad Bank
1 Crore
14 October 1995
Allahabad Bank & S.b.i.
30 Crore
26 July 1995
Allahabad Bank
70 Lak
04 October 1988
Allahabad Bank
1 Crore
19 July 1995
Allahabad Bank
3 Crore
02 June 2009
State Bank Of India
20 Crore
22 October 2008
Export Import Bank Of India
11 Crore
24 April 2010
Allahabad Bank
104 Crore
17 September 2009
Yes Bank Limited
30 Crore
20 March 2006
Export Import Bank Of India
12 Crore
08 June 2009
Axis Bank Limited
10 Crore
28 December 2005
Export Import Bank Of India
12 Crore
01 December 2006
Allahabad Bank
91 Crore
08 November 2006
Allahabad Bank
88 Crore
22 February 2008
Export Import Bank Of India
16 Crore
15 October 2009
Yes Bank Limited
30 Crore
27 October 2006
Export Import Bank Of India
5 Crore
26 November 2007
Yes Bank Limited
30 Crore
12 March 2009
State Bank Of Hyderabad
5 Crore
21 March 2005
Yes Bank Ltd.
15 Crore
05 May 1998
Allahabad Bank
148 Crore
17 April 1997
Allahabad Bank
41 Crore
13 February 1984
Allahabad Bank
16 Lak
25 July 1995
Allahabad Bank
70 Lak
05 May 1998
Allahabad Bank
14 Crore
05 January 1993
Allahabad Bank
10 Crore
19 July 2004
Idbi Bank Ltd.
3 Crore
14 August 1997
State Bank Of India
41 Crore
22 February 1995
State Bank Of India
14 Crore
14 August 1997
State Bank Of India
41 Crore
02 April 1997
Stressed Assets Stabilisation Fund
10 Crore
05 May 1995
Stressed Assets Stabilisation Fund
1 Crore
02 March 1993
Stressed Assets Stabilisation Fund
8 Crore
27 February 1998
State Bank Of Hyderabad;
15 Lak
14 October 1988
Andhra Pradesh Industrial Development Corporation
90 Lak
14 October 1988
Andhra Pradesh Industrial Development Corporation
90 Lak
01 June 1987
Andhra Pradesh State Financial Corporation
60 Lak
27 February 1989
State Bank Of Hyderabad;
18 Lak
09 April 1991
Dcl Finance Ltd.
1 Lak
28 March 1988
Andhra Pradesh Industrial Development Corporation
36 Lak
08 March 2011
Others
0
14 October 1988
Andhra Pradesh Industrial Development Corporation
0
18 October 2016
Others
0
01 June 1987
Andhra Pradesh State Financial Corporation
0
02 April 1997
Stressed Assets Stabilisation Fund
0
02 March 1993
Stressed Assets Stabilisation Fund
0
14 October 1988
Andhra Pradesh Industrial Development Corporation
0
05 May 1995
Stressed Assets Stabilisation Fund
0
08 June 2009
Axis Bank Limited
0
12 March 2009
State Bank Of Hyderabad
0
26 November 2007
Yes Bank Limited
0
01 December 2006
Allahabad Bank
0
08 November 2006
Allahabad Bank
0
27 February 1998
State Bank Of Hyderabad;
0
13 November 1992
Oriental Bank Of Commerce
0
09 April 1991
Dcl Finance Ltd.
0
13 March 1997
State Bank Of India
0
13 November 1992
Oriental Bank Of Commerce
0
25 July 1995
Allahabad Bank
0
05 May 1998
Allahabad Bank
0
14 August 1997
State Bank Of India
0
21 March 2005
Yes Bank Ltd.
0
21 December 2004
Export - Import Bank Of India
0
05 January 1993
Allahabad Bank
0
19 July 1995
Allahabad Bank
0
28 March 1988
Andhra Pradesh Industrial Development Corporation
0
24 March 2011
Barclays Bank Plc
0
26 August 2010
Export Import Bank Of India
0
17 April 2010
Axis Bank Limited
0
05 November 1992
Allahabad Bank
0
22 January 2010
Citi Bank N.a.
0
26 July 1995
Allahabad Bank
0
13 February 1984
Allahabad Bank
0
22 February 2008
Export Import Bank Of India
0
22 February 1995
State Bank Of India
0
17 April 1997
Allahabad Bank
0
05 May 1998
Allahabad Bank
0
27 October 2006
Export Import Bank Of India
0
07 November 1995
Export Import Bank Of India
0
27 February 1989
State Bank Of Hyderabad;
0
22 October 2008
Export Import Bank Of India
0
04 October 1988
Allahabad Bank
0
14 October 1995
Allahabad Bank & S.b.i.
0
02 June 2009
State Bank Of India
0
17 September 2009
Yes Bank Limited
0
28 December 2005
Export Import Bank Of India
0
20 March 2006
Export Import Bank Of India
0
22 June 2015
Citi Bank N.a.
0
22 December 2014
Citi Bank N.a.
0
10 May 2012
Icici Bank Limited
0
29 March 2011
Export Import Bank Of India
0
09 December 1994
Oriental Bank Of Commerce
0
15 October 2009
Yes Bank Limited
0
14 August 1997
State Bank Of India
0
19 July 2004
Idbi Bank Ltd.
0
24 April 2010
Allahabad Bank
0
13 November 1992
Central Bank Of Commrce;
0
08 March 2011
Others
0
14 October 1988
Andhra Pradesh Industrial Development Corporation
0
18 October 2016
Others
0
01 June 1987
Andhra Pradesh State Financial Corporation
0
02 April 1997
Stressed Assets Stabilisation Fund
0
02 March 1993
Stressed Assets Stabilisation Fund
0
14 October 1988
Andhra Pradesh Industrial Development Corporation
0
05 May 1995
Stressed Assets Stabilisation Fund
0
08 June 2009
Axis Bank Limited
0
12 March 2009
State Bank Of Hyderabad
0
26 November 2007
Yes Bank Limited
0
01 December 2006
Allahabad Bank
0
08 November 2006
Allahabad Bank
0
27 February 1998
State Bank Of Hyderabad;
0
13 November 1992
Oriental Bank Of Commerce
0
09 April 1991
Dcl Finance Ltd.
0
13 March 1997
State Bank Of India
0
13 November 1992
Oriental Bank Of Commerce
0
25 July 1995
Allahabad Bank
0
05 May 1998
Allahabad Bank
0
14 August 1997
State Bank Of India
0
21 March 2005
Yes Bank Ltd.
0
21 December 2004
Export - Import Bank Of India
0
05 January 1993
Allahabad Bank
0
19 July 1995
Allahabad Bank
0
28 March 1988
Andhra Pradesh Industrial Development Corporation
0
24 March 2011
Barclays Bank Plc
0
26 August 2010
Export Import Bank Of India
0
17 April 2010
Axis Bank Limited
0
05 November 1992
Allahabad Bank
0
22 January 2010
Citi Bank N.a.
0
26 July 1995
Allahabad Bank
0
13 February 1984
Allahabad Bank
0
22 February 2008
Export Import Bank Of India
0
22 February 1995
State Bank Of India
0
17 April 1997
Allahabad Bank
0
05 May 1998
Allahabad Bank
0
27 October 2006
Export Import Bank Of India
0
07 November 1995
Export Import Bank Of India
0
27 February 1989
State Bank Of Hyderabad;
0
22 October 2008
Export Import Bank Of India
0
04 October 1988
Allahabad Bank
0
14 October 1995
Allahabad Bank & S.b.i.
0
02 June 2009
State Bank Of India
0
17 September 2009
Yes Bank Limited
0
28 December 2005
Export Import Bank Of India
0
20 March 2006
Export Import Bank Of India
0
22 June 2015
Citi Bank N.a.
0
22 December 2014
Citi Bank N.a.
0
10 May 2012
Icici Bank Limited
0
29 March 2011
Export Import Bank Of India
0
09 December 1994
Oriental Bank Of Commerce
0
15 October 2009
Yes Bank Limited
0
14 August 1997
State Bank Of India
0
19 July 2004
Idbi Bank Ltd.
0
24 April 2010
Allahabad Bank
0
13 November 1992
Central Bank Of Commrce;
0
Documents
Form DPT-3-03022021-signed
Approval letter for extension of AGM;-26112020
Optional Attachment-(2)-26112020
Copy of MGT-8-26112020
ROC_20200331_R72338940_INVESTORS_20201126122345.xlsx
Optional Attachment-(1)-26112020
Form MGT-7-26112020_signed
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-13112020
XBRL document in respect Consolidated financial statement-13112020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-13112020
Optional Attachment-(1)-13112020
Approval letter of extension of financial year of AGM-13112020
Form AOC-4(XBRL)-13112020_signed
Form MR-1-29102020_signed
Optional Attachment-(1)-29102020
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -29102020
Copy of certificate by the Nomination and Remuneration Committee of the company, if any, to the effect that the remuneration is-29102020
Copy of board resolution-29102020
Copy of shareholders resolution-29102020
Form MGT-14-27102020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-26102020
Form MGT-15-20102020_signed
List of allottees. Attach separate list for each allotment (refer instruction kit for format).If not attached, then it shall be submitted separately in a CD.-28092020
Copy of Board or Shareholders? resolution-28092020
Form PAS-3-28092020_signed
Form MR-1-06082020_signed
Copy of letter of consent to act as Managing Director/ Whole time Director/Manager ; -05082020
Copy of certificate by the Nomination and Remuneration Committee of the company, if any, to the effect that the remuneration is-05082020
Optional Attachment-(1)-05082020
Copy of shareholders resolution-05082020
